Tag: Addiction

  • Opioid dependence in Scotland remains high but largely stable, study shows

    Opioid dependence in Scotland remains high but largely stable, study shows

    [ad_1]

    Opioid dependence in Scotland remains high but largely stable, according to a new University of Bristol-led analysis published in Addiction today [18 April] and by Public Health Scotland. The study is the first to estimate the number of people dependent on opioid drugs (such as heroin), and who are in or could benefit from drug treatment, among Scotland’s population since 2015/2016 estimates were published.

    Scotland has one of the highest rates of drug-related deaths in Europe, with the number of these more than doubling between 2011 and 2020. At 250-300 per million population in 2021-22, Scotland’s rate of drug-related deaths was sixteen times higher than the average in the European Union and on par with rates in North America. As part of the response to the public health emergency in drug-related deaths, the Scottish Government-commissioned study sought to understand whether the number of people with opioid dependence among its general publication is also increasing.

    To predict how many people aged 15 to 64 years old are opioid dependent, researchers from Bristol’s National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation applied a statistical modelling technique using data from Public Health Scotland’s Scottish Public Health Drug Linkage Programme, including information on people in drug treatment called opioid agonist treatment (OAT – primarily methadone and buprenorphine) and data on opioid-related mortality and hospital admissions.

    In these new estimates, researchers found the prevalence of opioid dependence in Scotland to have been relatively stable between 2014/15 to 2019/20, with 47,100 people estimated to be opioid-dependent in 2019/20 – which is 1.3 per cent of the adult population aged 15-64.

    While there was weak evidence of a small reduction in the total number of people with opioid dependence since 2014/15, the extent of any change was estimated to be small (-0.07 per cent or -2,000 people). There was evidence that the population of people with opioid dependence were ageing, with estimates of the number of people aged 15 to 34 years old reducing by 5,100 and the number aged 50 to 64 years old increasing by 2,800 between 2014/15 and 2019/20.

    The research team also estimated that over 60 per cent of the population of people who were opioid-dependent received OAT at least once during 2019/20 and nearly 75 per cent had been in drug treatment in the last five years.

    Dr Hayley Jones, Associate Professor in Medical Statistics in the Bristol Medical School: Population Health Sciences (PHS), lead author and developer of the method (Multi-Parameter Estimation of Prevalence) used in Scotland, said: “This is the first time that trends in the prevalence of people with opioid dependence have been produced in Scotland, showing the value of and making the most of the high-quality linked data sets that are available there.

    “The method can be used to update the estimates in future, and can be applied in other countries that create comprehensive records of people in drug treatment and link these to data on drug-related harms.”

    Importantly, our estimates suggest the substantial increase in drug-related deaths in Scotland is not due to increases in the underlying population of people with opioid dependence but because of increases in the risk of death experienced by people with opioid dependence in Scotland.”


    Professor Matt Hickman, co-first author and director of the NIHR HPRU at the University of Bristol

    Professors Sharon Hutchinson and Andrew McAuley, co-authors and lead researchers at Glasgow Caledonian University, explained: “We showed that exposure to drug treatment in Scotland is high compared to many countries worldwide. The challenge in Scotland and rest of UK, however, is to retain people in drug treatment for longer and to determine what other interventions are required to effect change at the population level – and bring down the number of drug-related deaths.”

    The public health surveillance study, commissioned by the Scottish Government, is a collaboration between Public Health Scotland, the University of Bristol, and Glasgow Caledonian University.

    Source:

    Journal reference:

    Markoulidakis, A., et al. (2024) Prevalence of opioid dependence in Scotland 2015–2020: A multi-parameter estimation of prevalence (MPEP) study. Addiction. doi.org/10.1111/add.16500.

    [ad_2]

    Source link

  • Excessive internet use plus lack of sleep, exercise linked to teen truancy and school absence

    Excessive internet use plus lack of sleep, exercise linked to teen truancy and school absence

    [ad_1]

    Spending too much time online to the point of compulsion and the neglect of other necessary activities, plus not sleeping or exercising enough, are linked to a heightened risk of both truancy and school absence due to illness among teens, finds research published online in the Archives of Disease in Childhood.

    Teenage girls seem to be more vulnerable than teenage boys to excessive internet use, but getting the recommended quota of shut eye and exercise and having a trusting relationship with parents all seem to be protective, the findings indicate.

    Although differences in how excessive internet use is assessed and categorized can make it difficult to quantify, digital media may be a factor tempting teens to stay home from school, and may also hinder learning through lack of sleep, suggest the researchers.

    To try and gauge what impact excessive internet use might have on school attendance and what, if any, mitigating factors there might be, the researchers used data from the School Health Promotion study, a national biennial survey conducted in Finland and managed by the Institute for Health and Welfare.

    They focused on 86,270 year 8 and 9 pupils aged 14 to 16. The teens were specifically asked about their relationship with their parents in terms of how often they shared concerns with them (often to fairly rarely), as well as how long they slept every night, and how many days of the week they had been on the move for at least an hour.

    Excessive internet use was assessed using a validated (Excessive Internet Use; EIU) scale consisting of 5 components indicating compulsion; neglect of family, friends, and study; anxiety if not online; and failure to eat or sleep because of being online.

    Respondents were asked to estimate how often they experienced each of these, scoring them from 1 (‘never’) to 4 (‘very often’) to provide an overall average. 

    And they provided information on how many times during the most recent school year they had played truant and/or had been absent due to illness, ranging from ‘not at all’ through to ‘daily or almost daily’.

    The EIU scale average score was just under 2; and just over 2% (1881) of participants scored the maximum of 4. Girls spent more time online than boys: they were 96% more likely to fall into the excessive internet use category than boys (79%), possibly because they tend to use social media more than boys, suggest the researchers.

    On average, the teens slept 8 hours on school nights, and 9 hours on weekend nights. But more than  a third (35%) clocked up fewer than 8 hours on school nights, and 11% slept fewer than 8 hours at the weekend.

    Participants reported physical activity for at least an hour on 4 days of the preceding week and vigorous physical activity for 2-3 hours a week. But a third reported low levels of physical activity—fewer than 3 days a week. Boys were more likely than girls to report no, or daily, physical activity.

    Overall, 3-4% of respondents reported high rates of school absence. Boys reported more truancy than girls, who reported more medically explained absences than boys.

    Older age was associated with a greater likelihood of truancy. But spending an excessive amount of time online was associated with an increased risk of both truancy (38% heightened risk) and medically explained school absences (24% heightened risk). 

    Good parental relations, longer nightly weekday sleep, and physical activity all emerged as significantly protective, with more of each factor associated with a steadily decreasing risk of both truancy and school absences due to illness. 

    Being able to talk about concerns with parents was most strongly associated with the lowest risk of either type of school absence. Teens who often felt able to share troubling issues with their parents were 59% less likely to play truant and 39% less likely to be absent from school due to illness.

    This is an observational study, and as such, no firm conclusions can be drawn about causal factors, and the researchers acknowledge that the School Health Promotion study didn’t include information on the type of internet use teens engaged in.

    “Despite the limitations, our results have important implications for promotion of health and educational attainment,” suggest the researchers.

    “Our results are relevant for professionals organising and working in school health and wellbeing services, especially when professionals meet students whose school absences raise concern,” they add.

    Source:

    Journal reference:

    Kosola, S., et al. (2024). Associations of excessive internet use, sleep duration and physical activity with school absences: a cross-sectional, population-based study of adolescents in years 8 and 9. Archives of Disease in Childhood. doi.org/10.1136/archdischild-2023-326331.

    [ad_2]

    Source link

  • To stop fentanyl deaths in Philadelphia, knocking on doors and handing out overdose kits

    To stop fentanyl deaths in Philadelphia, knocking on doors and handing out overdose kits

    [ad_1]

    On a narrow street lined with row houses and an auto body shop in the Kensington neighborhood of North Philadelphia, Marsella Elie climbs a home’s front steps and knocks hard on the door.

    A middle-aged man appears with a wary look on his face.

    “Hello, sir, how are you doing today?” asked Elie, wearing a royal-blue jacket embroidered with the city government’s Liberty Bell logo. “My name is Marsella. I’m working with the city. You heard about the overdoses that are going around in the neighborhood, right?”

    The man gives a cautious nod.

    Elie gestures to the pamphlets she’s holding about drug overdoses and addiction treatment programs. She holds up a box of Narcan, a brand of naloxone, which can reverse an opioid overdose.

    “What we’re trying to do is get this in everybody’s household. Have you ever heard of this before?” Elie asked before handing the man a tote bag filled with more pamphlets, fentanyl test strips, and the box of Narcan.

    Elie and other part-time city workers and volunteers are part of a large-scale, citywide door-to-door campaign in Philadelphia that aims to equip homes with naloxone and other drug overdose prevention supplies.

    City officials hope that this proactive approach will normalize naloxone as an everyday item in the medicine cabinet, and prevent people from dying of overdoses, especially Black residents.

    In Philadelphia in 2022, a record 1,413 people died from drug overdoses, according to city data. Among Black residents, deaths were up 20% from the year before, with many happening in private homes.

    “The best thing we can do to make these things more accessible is to just give them to people,” said Keli McLoyd, deputy director of the city’s Opioid Response Unit, speaking about the tote bag with naloxone and other supplies. “We’re not asking you if you’re using drugs. The goal here is really to build sort of a collective responsibility. As Black and brown folks, as we saw during the covid epidemic, nobody’s coming to save us. For us, this is a tool that we can use to save ourselves.”

    The canvassing initiative aims to take prevention supplies directly to people who might not otherwise seek it out themselves, and to spread awareness about overdoses beyond Kensington, the epicenter of the city’s addiction epidemic. Canvassers plan to knock on more than 100,000 doors in Philadelphia’s “hot spots” — ZIP codes with escalating rates of opioid overdoses, many in minority communities.

    Widening racial disparities in overdose deaths are among the long-term consequences of the war on drugs, McLoyd said. Policies from that national anti-drug campaign led to decades of aggressive police tactics, racial profiling, and lengthy prison sentences, disproportionately affecting people of color and their communities.

    Research shows that Black Americans still account for a disproportionate number of drug arrests and child protective services.

    “Because of that, it’s very clear why Black or brown people might be hesitant to raise their hand and say, ‘I’m a person who uses drugs, I need those resources,’” McLoyd said.

    Other communities have distributed naloxone and other supplies, albeit on a smaller scale than Philadelphia.

    What Philadelphia is doing could become a model for other densely populated places, said Daliah Heller, vice president of drug use initiatives at Vital Strategies, a public health organization working with local governments in seven states to address the opioid epidemic.

    “There’s something intensely personal about a human engagement,” Heller said. “And somebody knocking at your door to talk about drug use and overdose risk and that there’s something that can be done, I think is really powerful.”

    Over the years, naloxone has become more accessible than ever before, Heller pointed out. It can now be ordered online and through the mail, it’s available in specialized vending machines, and some drugstores now sell Narcan nasal spray over the counter.

    But tens of thousands of Americans are still dying from opioid overdoses every year. That means prevention efforts and messaging about the crisis are still not reaching some people, Heller said. And to her, reaching people means meeting them where they are. “That means physically, that means in terms of what they know about something, what their perception is of something, and their beliefs,” she said. “We need to think like that when we think about naloxone distribution.”

    The Philadelphia canvassing project is funded in part by the city’s share of settlement payouts from national lawsuits against opioid manufacturers and distributors. The city is set to receive about $200 million over roughly 18 years from settlements with AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson.

    The initiative is staffed by many of the same people who initially started canvassing as part of the 2020 census count.

    Not everyone answers the door for the canvassers. Some aren’t home when they come around. In those cases, workers hang a flyer on the door handle that offers information about overdose risks and contacts for further resources. The teams of canvassers, often with language interpreters, later make a second sweep through a neighborhood to reach people they missed the first time.

    On a recent Thursday, Philadelphia canvassers were knocking on doors in the Franklinville and Hunting Park neighborhoods. In this ZIP code, about 85 people died of drug overdoses in 2022, according to city data. That’s fewer than the 193 people who died of overdoses in Kensington in 2022, but much higher than the few deaths seen in the city’s most affluent neighborhoods.

    The canvassers approached a resident, Katherine Camacho, on the sidewalk, as she came out of her garage. Camacho told the teams she was aware of the overdose problem in her community and then eagerly accepted a box of Narcan.

    “I will carry this with me, because, like I said, sometimes you’re in the street driving somewhere and you could save a life,” Camacho told them. “And if you don’t have these things, it’s harder to do so, right?”

    Camacho said she’s seen how the opioid crisis has caused suffering in her neighborhood and across the city. As for Philadelphia’s canvassing effort, she said she believes that “God is putting these people to help.”

    As she headed into her house carrying the box of Narcan, Camacho said she wanted to do her part to help, too.




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link

  • UC San Diego researchers discover genetic connections to alcohol consumption

    UC San Diego researchers discover genetic connections to alcohol consumption

    [ad_1]

    A research group centered at the University of California San Diego School of Medicine has drilled deep into a dataset of over 3 million individuals compiled by the direct-to-consumer genetics company 23andMe, Inc., and found intriguing connections between genetic factors influencing alcohol consumption and their relationship with other disorders.

    The study was recently published in the Lancet eBioMedicine.

    Sandra Sanchez-Roige, Ph.D., corresponding author and associate professor at UC San Diego School of Medicine Department of Psychiatry, explained that the study used genetic data to broadly classify individuals as being European, Latin American and African American. Such classifications “are needed to avoid a statistical genetics pitfall called population stratification,” noted co-author Abraham A. Palmer, Ph.D., professor and vice chair for basic research in the psychiatry department.

    The researchers analyzed genetic data from the 3 million 23andMe research participants, focusing on three specific little snippets of DNA known as single-nucleotide polymorphisms, or SNPs. Sanchez-Roige explained that variants, or alleles, of these particular SNPs are “protective” against a variety of alcohol behaviors, from excessive alcohol drinking to alcohol use disorder.

    One of the alcohol-protective variants they considered is very rare: the most prevalent among the three alleles found in the study showed up in 232 individuals of the 2,619,939 European cohort, 29 of the 446,646 Latin American cohort and in 7 of the 146,776 African American cohort; others are much more common. These variants affect how the body metabolizes ethanol -; the intoxicating chemical in alcoholic beverages.

    The people who have the minor allele variant of the SNP convert ethanol to acetaldehyde very rapidly. And that causes a lot of negative effects.”


    Sandra Sanchez-Roige, Ph.D., corresponding author and associate professor at UC San Diego School of Medicine Department of Psychiatry

    She went on to say that the resulting nausea eclipses any pleasurable effects of alcohol -; think of a bad hangover that sets in almost immediately.

    “These variants are primarily associated with how much someone may consume alcohol,” she said. “And they also tend to prevent alcohol use disorder, because these variants are primarily associated with the quantity of alcohol someone may drink.”

    Sanchez-Roige explained that the SNP variants’ influence on alcohol consumption are well researched, but her group took a “hypothesis-free” approach to the 23andMe dataset, which contains survey data on thousands of traits and behaviors. The researchers wanted to find out if the three SNP variants might have any other effects beyond alcohol consumption.

    Sanchez-Roige and Palmer noted that their group has developed a 10-year partnership with 23andMe that has focused on numerous traits, especially those with relevance for addiction. This work is the basis of an academic collaboration through the 23andMe Research Program. 

    They data-mined the analyses of DNA from saliva samples submitted by consenting 23andMe research participants, as well as the responses to the surveys of health and behavior available from the 23andMe database, and found a constellation of associations, not necessarily connected with alcohol. Individuals with the alcohol-protecting alleles had generally better health, including less chronic fatigue and needing less daily assistance with daily tasks.

    But the paper notes individuals with the alcohol-protective alleles also had worse health outcomes in certain areas: more lifetime tobacco use, more emotional eating, more Graves’ disease and hyperthyroidism. Individuals with the alcohol-protective alleles also reported totally unexpected differences, such as more malaria, more myopia and several cancers, particularly more skin cancer and lung cancer, and more migraine with aura. 

    Sanchez-Roige acknowledged that there is a chicken-and-egg aspect to their findings. For example: Cardiovascular disease is just one of a number of maladies known to be associated with alcohol consumption. “So is alcohol consumption leading to these conditions?” she asks. Palmer finishes the thought: “Or do these genetic differences influence traits like malaria and skin cancer in a manner that is independent of alcohol consumption?”

    Sanchez-Roige said that such broad, hypothesis-free studies are only possible if researchers have access to very large sets of data. Many datasets, including the one used in the study, rely heavily on individuals with European ancestry.

    “It is important to include individuals from different ancestral backgrounds in genetic studies because it provides a more complete understanding of the genetic basis of alcohol behaviors and other conditions, all of which contributes to a more inclusive and accurate understanding of human health,” she said. “The study of only one group of genetically similar individuals (for example, individuals of shared European ancestry) could worsen health disparities by aiding discoveries that will disproportionately benefit only that population.”

    She said their study opens numerous doors for future research, chasing down possible connections between the alcohol-protective alleles and conditions that have no apparent connection with alcohol consumption.

    “Understanding the underlying mechanisms of these effects could have implications for treatments and preventative medicine,” Sanchez-Roige noted. 

    Co-authors on the paper from the University of California San Diego School of Medicine Department of Psychiatry are Mariela V. Jennings, Natasia S. Courchesne-Krak, Renata B. Cupertino and Sevim B. Bianchi. Sandra Sanchez-Roige is also associated with the Department of Medicine, Division of Genetic Medicine, Vanderbilt University.

    Other co-authors are: José Jaime Martínez-Magaña, Department of Psychiatry, Division of Human Genetics, Yale University School of Medicine; Laura Vilar-Ribó, Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain; Alexander S. Hatoum, Department of Psychology & Brain Sciences, Washington University in St. Louis; Elizabeth G. Atkinson, Department of Molecular and Human Genetics, Baylor College of Medicine; Paola Giusti-Rodriguez, Department of Psychiatry, University of Florida College of Medicine; Janitza L. Montalvo-Ortiz, Department of Psychiatry, Division of Human Genetics, Yale University School of Medicine, National Center of Posttraumatic Stress Disorder, VA CT Healthcare Center; Joel Gelernter, VA CT Healthcare Center, Department of Psychiatry, West Haven CT; and Departments of Psychiatry, Genetics & Neuroscience, Yale Univ. School of Medicine; María Soler Artigas, Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Mental Health, Hospital Universitari Vall d’Hebron, Barcelona; Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid; and Department of Genetics, Microbiology, and Statistics, Faculty of Biology, Universitat de Barcelona; Howard J. Edenberg, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine; and the 23andMe Inc. Research Team, including Sarah L. Elson and Pierre Fontanillas.

    The study was funded, in part, by Tobacco-Related Disease Research Program grants T32IR5226 and 28IR-0070, National Institute of Health (NIH) National Institute of Drug Abuse (NIDA) DP1DA054394, and NIH National Institute of Mental Health (NIMH) R25MH081482. 

    Source:

    Journal reference:

    Jennings, M. V., et al. (2024) A phenome-wide association and Mendelian randomisation study of alcohol use variants in a diverse cohort comprising over 3 million individuals. Lancet eBioMedicine. doi.org/10.1016/j.ebiom.2024.105086.

    [ad_2]

    Source link

  • More kids are dying of drug overdoses. Could pediatricians do more to help?

    More kids are dying of drug overdoses. Could pediatricians do more to help?

    [ad_1]

    A 17-year-old boy with shaggy blond hair stepped onto the scale at Tri-River Family Health Center in Uxbridge, Massachusetts.

    After he was weighed, he headed for an exam room decorated with decals of planets and cartoon characters. A nurse checked his blood pressure. A pediatrician asked about school, home life, and his friendships.

    This seemed like a routine teen checkup, the kind that happens in thousands of pediatric practices across the U.S. every day — until the doctor popped his next question.

    “Any cravings for opioids at all?” asked pediatrician Safdar Medina. The patient shook his head.

    “None, not at all?” Medina said again, to confirm.

    “None,” said the boy named Sam, in a quiet but confident voice.

    Only Sam’s first name is being used for this article because if his full name were publicized he could face discrimination in housing and job searches based on his prior drug use.

    Medina was treating Sam for an addiction to opioids. He prescribed a medication called buprenorphine, which curbs cravings for the more dangerous and addictive opioid pills. Sam’s urine tests showed no signs of the Percocet or OxyContin pills he had been buying on Snapchat, the pills that fueled Sam’s addiction.

    “What makes me really proud of you, Sam, is how committed you are to getting better,” said Medina, whose practice is part of UMass Memorial Health.

    The American Academy of Pediatrics recommends offering buprenorphine to teens addicted to opioids. But only 6% of pediatricians report ever doing do, according to survey results.

    In fact, buprenorphine prescriptions for adolescents were declining as overdose deaths for 10- to 19-year-olds more than doubled. These overdoses, combined with accidental opioid poisonings among young children, have become the third-leading cause of death for U.S. children.

    “We’re really far from where we need to be and we’re far on a couple of different fronts,” said Scott Hadland, the chief of adolescent medicine at Mass General for Children and a co-author of the study that surveyed pediatricians about addiction treatment.

    That survey showed that many pediatricians don’t think they have the right training or personnel for this type of care — although Medina and other pediatricians who do manage patients with addiction say they haven’t had to hire any additional staff.

    Some pediatricians responded to the survey by saying they don’t have enough patients to justify learning about this type of care, or don’t think it’s a pediatrician’s job.

    “A lot of that has to do with training,” said Deepa Camenga, associate director for pediatric programs for the Yale Program in Addiction Medicine. “It’s seen as something that’s a very specialized area of medicine and, therefore, people are not exposed to it during routine medical training.”

    Camenga and Hadland said medical schools and pediatric residency programs are working to add information to their curricula about substance use disorders, including how to discuss drug and alcohol use with children and teens.

    But the curricula aren’t changing fast enough to help the number of young people struggling with an addiction, not to mention those who die after taking just one pill.

    In a twisted, deadly development, drug use among adolescents has declined — but drug-associated deaths are up.

    The main culprits are fake Xanax, Adderall, or Percocet pills laced with the powerful opioid fentanyl. Nearly 25% of recent overdose deaths among 10- to 19-year-olds were traced to counterfeit pills.

    “Fentanyl and counterfeit pills is really complicating our efforts to stop these overdoses,” said Andrew Terranella, the Centers for Disease Control and Prevention’s expert on adolescent addiction medicine and overdose prevention. “Many times these kids are overdosing without any awareness of what they’re taking.”

    Terranella said pediatricians can help by stepping up screening for — and having conversations about — all types of drug use.

    He also suggests pediatricians prescribe more naloxone, the nasal spray that can reverse an overdose. It’s available over the counter, but Terranella, who practices in Tucson, Arizona, believes a prescription may carry more weight with patients.

    Back in the exam room, Sam was about to get his first shot of Sublocade, an injection form of buprenorphine that lasts 30 days. Sam is switching to the shots because he didn’t like the taste of Suboxone, oral strips of buprenorphine that he was supposed to dissolve under his tongue. He was spitting them out before he got a full dose.

    Many doctors also prefer to prescribe the shots because patients don’t have to remember to take them every day. But the injection is painful. Sam was surprised when he learned that it would be injected into his belly over the course of 20-30 seconds.

    “Is it almost done?” Sam asked, while a nurse coaches him to breathe deeply. When it was over, staffers joked out loud that even adults usually swear when they get the shot. Sam said he didn’t know that was allowed. He’s mostly worried about any residual soreness that might interfere with his evening plans.

    “Do you think I can snowboard tonight?” Sam asked the doctor.

    “I totally think you can snowboard tonight,” Medina answered reassuringly.

    Sam was going with a new buddy. Making new friends and cutting ties with his former social circle of teens who use drugs has been one of the hardest things, Sam said, since he entered rehab 15 months ago.

    “Surrounding yourself with the right people is definitely a big thing you want to focus on,” Sam said. “That would be my biggest piece of advice.”

    For Sam, finding addiction treatment in a medical office jammed with puzzles, toys, and picture books has not been as odd as he thought it would be.

    He mom, Julie, had accompanied him to this appointment. She said she’s grateful the family found a doctor who understands teens and substance use.

    Before he started visiting the Tri-River Family Health Center, Sam had seven months of residential and outpatient treatment — without ever being offered buprenorphine to help control cravings and prevent relapse. Only 1 in 4 residential programs for youth offer it. When Sam’s cravings for opioids returned, a counselor suggested Julie call Medina.

    “Oh my gosh, I would have been having Sam here, like, two or three years ago,” Julie said. “Would it have changed the path? I don’t know, but it would have been a more appropriate level of care for him.”

    Some parents and pediatricians worry about starting a teenager on buprenorphine, which can produce side effects including long-term dependence. Pediatricians who prescribe the medication weigh the possible side effects against the threat of a fentanyl overdose.

    “In this era, where young people are dying at truly unprecedented rates of opioid overdose, it’s really critical that we save lives,” said Hadland. “And we know that buprenorphine is a medication that saves lives.”

    Addiction care can take a lot of time for a pediatrician. Sam and Medina text several times a week. Medina stresses that any exchange that Sam asks to be kept confidential is not shared.

    Medina said treating substance use disorder is one of the most rewarding things he does.

    “If we can take care of it,” he said, “We have produced an adult that will no longer have a lifetime of these challenges to worry about.”




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link

  • UT Health San Antonio launches Be Well Institute for substance use research and treatment

    UT Health San Antonio launches Be Well Institute for substance use research and treatment

    [ad_1]

    The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is establishing the Be Well Institute on Substance Use and Related Disorders, a pioneering initiative dedicated to advancing research, education and evidence-based treatments.

    The new institute includes the current Be Well Texas initiative of UT Health San Antonio as part of a new overall comprehensive center of excellence with national scope for research, clinical and public health programs, as well as education and community engagement to advance the field addressing addiction and related conditions.

    The goal of the Be Well Institute is to be a nationally premiere substance use and addiction institute for clinical care and research to advance the understanding of substance use.

    The institute will support grants and contracts, partner with organizational entities at UT Health San Antonio whose activities are relevant to these priorities and provide person-centered, interprofessional and comprehensive care. It also will launch clinical and translational research programs to significantly advance the understanding of substance use to scientific discovery and into daily practice more quickly to improve health and reduce sickness and death.

    This institute will lead transformational change in addressing substance use and substance use disorders throughout Texas and the nation.”


    Robert A. Hromas, MD, FACP, acting president of UT Health San Antonio

    “We support the discovery, development and implementation of new treatments, or more effective use of current treatments, and this important effort will facilitate the recruitment of outstanding scientists and clinicians to UT Health San Antonio,” he said, “accelerating collaboration among scientists, educators and clinicians to discover, validate and implement new treatments, and serve as a vehicle for partnerships among stakeholders in the community to include scientists, providers and policymakers.”

    UT Health San Antonio is the largest academic research institution in South Texas with an annual research portfolio of $413 million. Spearheaded by Be Well Texas founding director Jennifer Sharpe Potter, PhD, MPH, vice president for research at UT Health San Antonio, the new institute marks a significant milestone in UT Health San Antonio’s commitment to addressing the complex challenges posed by substance use.

    It will provide compassionate and transformational care of people who use substances and those with substance use disorder (SUD) – or co-occurring mental health disorders – through innovative research, local networks and engagement, thereby removing stigma and supporting recovery for patients, their families and communities.

    A highly integrated, collaborative center

    With more than $50 million in National Institutes of Health, state and other federal funding annually, the Be Well Institute will work as a highly integrated and collaborative center across the university and represent a comprehensive framework and programming for advancing the understanding and treatment of substance use disorders.

    Through a diverse array of statewide initiatives, including the Be Well Provider Network, the Be Well Clinic, the Center for Substance Use Training and Telementoring, and the Texas Substance Use Symposium, the institute seeks to expand access to services and support for Texans and beyond.

    With support from the National Institute on Drug Abuse Clinical Trials Network and other federal funding, the institute includes research, medical interventions and evidence-based treatments, psychological therapies, social and peer support, counseling on lifestyle changes, follow-up care, provider training and education, and many community outreach and educational initiatives.

    Substance use is a significant public health problem that includes several challenges, from the illicit use of substances that have been available for centuries, such as opioids, to drugs that have appeared more recently, like synthetic cannabinoids. Substance use and other mental health disorders worsened significantly during the COVID-19 pandemic. Substance use among many mentally ill patients also increased during that time as many sought to self-medicate.

    Although opioids are most prominent in news headlines, the most problematic drugs of abuse in some regions of the United States, including South Texas, are not opioids, but alcohol, marijuana and stimulants like methamphetamine. Alcohol use is a major contributor to morbidity, including cancer, and mortality. The rate of alcohol-related deaths in the U.S. doubled from 1999 to 2017.

    There currently are no FDA-approved medications for treating substance use disorder outside of opioids and alcohol. Thus, the exploding use of stimulants and marijuana represents a vast unmet medical need.

    The worsening overdose epidemic exemplifies the desperate need to improve prevention and treatment of SUD through research and programmatic efforts. An unprecedented 107,000 Americans died in 2022 from drug overdose, the highest rate ever recorded.

    Often lost in the national discussion of this medical crisis is the fact that this dramatic increase in opioid use and overdose occurred despite the availability of FDA-approved medications that are effective in many patients: methadone, buprenorphine and naltrexone for opioid use disorder (OUD) and naloxone for opioid overdose. Discovering and advancing new and innovative approaches for treating opioid overdose and OUD is a critically important endeavor.

    Investigators at UT Health San Antonio are conducting state-of-the-art research exploring novel approaches for understanding SUD that will uncover new targets and new methods for treatment.

    Similarly, UT Health San Antonio faculty are at the forefront of addressing SUD statewide, including establishing statewide treatment networks, workforce development initiatives and distribution of life-saving naloxone to traditional and non-traditional first responders. Collectively, what is available at UT Health San Antonio is unique in Texas and ready to be expanded nationally.

    About Jennifer Sharpe Potter

    As a nationally recognized public health scientist and practitioner, Potter leads the state in groundbreaking research and treatment aimed at mitigating addiction, substance use disorders and related disorders. Her expertise spans the development, dissemination and implementation of evidence-based practices to support individuals grappling with substance use disorders.

    In her role as vice president for research at UT Health San Antonio, Potter provides strategic oversight over the institution’s research initiatives, ensuring the university’s continued pursuit of excellence in scientific inquiry and innovation. Her leadership also extends to pivotal roles as principal investigator of UT Health San Antonio’s Institute for Integration of Medicine and Science (IIMS) and the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN), underscoring her commitment to advancing the frontiers of substance use research.

    Prior to joining UT Health San Antonio, Potter was with Harvard Medical School and McLean Hospital in Belmont, Mass. She earned her doctorate in clinical psychology from the University of Georgia and her Master of Public Health from the Rollins School of Public Health at Emory University.

    “The launch of the Be Well Institute heralds a new era of collaboration and innovation in the field of substance use research and care,” Potter said, “and stakeholders from across the academic, health care and public sectors are encouraged to join us in this vital endeavor as we strive to improve the lives of individuals and communities affected by substance use disorders.”

    [ad_2]

    Source link

  • Promising new compound reduces alcohol dependence in animal studies

    Promising new compound reduces alcohol dependence in animal studies

    [ad_1]

    Scripps Research scientists have found that LY2444296-;a compound that selectively blocks the kappa opioid receptor (KOP)-;may reduce drinking in cases of alcohol dependence in animal studies. The findings, which were published March 9, 2024, in Scientific Reports, could eventually inform new treatment options for people who experience alcohol use disorder (AUD).

    Compounds designed to selectively block the KOP are very promising because this receptor is involved in a lot of mental illnesses, such as anxiety and depression. The KOP system is also important in alcohol use disorder, so the idea is if it’s targeted and blocked, you can stop alcohol abuse.”


    Rémi Martin-Fardon, PhD, Associate Professor, Department of Molecular Medicine

    The KOP system controls brain circuits that affect a range of neurological processes, including addiction, emotion, pain and reward seeking. Both acute and chronic exposure to alcohol negatively affects this system, according to the study’s first author, Francisco Flores-Ramirez, PhD, a postdoctoral fellow at Scripps Research.

    For their study, Martin-Fardon and Flores-Ramirez sought to find out whether orally administering LY2444296 could decrease alcohol consumption in rats that formed alcohol dependency. The aim was to mitigate withdrawal symptoms, which would hypothetically lead to reduced alcohol intake. Once rats received LY2444296 at doses as low as 3 mg per kg following 8 hours of abstinence-;when acute withdrawal symptoms typically start-; withdrawal signs and alcohol consumption tapered down significantly. The researchers also determined that LY2444296 may be innocuous, as it had neither a positive nor negative effect on rats without alcohol dependency.

    Martin-Fardon and his team didn’t expect LY2444296 to reduce withdrawal signs after only 8 hours of alcohol abstinence because earlier studies showed that other compounds capable of binding to the KOP had no effect on alcohol withdrawal. The scientists don’t yet know why LY2444296 was effective in the present study, and they plan to investigate further.

    “People drink to get rid of the sensations of withdrawal,” Martin-Fardon says. He added that withdrawal is associated with physical pain, and that oftentimes, “the only thing that can fix the problem is to have a drink.” But if LY2444296 is taken before withdrawal symptoms begin, “you can decrease the symptoms, so you feel better and drink less.”

    Still, the question remains which specific parts of the brain are best targeted to mitigate withdrawal symptoms. Next on their agenda, Martin-Fardon and Flores-Ramirez hope to determine whether LY24444296 can block the effects of stress and other cues that can trigger alcohol relapse.

    “We’re also interested in what brain regions are changing as a function of alcohol dependence,” Flores-Ramirez says. “Maybe we could target them to see if the compound could reverse both drinking and relapse behavior.”

    Source:

    Journal reference:

    Flores-Ramirez, F. J., et al. (2024). LY2444296, a κ-opioid receptor antagonist, selectively reduces alcohol drinking in male and female Wistar rats with a history of alcohol dependence. Scientific Reports. doi.org/10.1038/s41598-024-56500-9.

    [ad_2]

    Source link

  • Is smoking linked to abdominal obesity?

    Is smoking linked to abdominal obesity?

    [ad_1]

    Previously, Mendelian randomization (MR) studies have explored the causal relationship between smoking and abdominal obesity using a single genetic variant for smoking heaviness. Similarly, a recent Addiction study uses multiple genetic instruments to estimate the causal relationship between smoking and abdominal obesity.

    Study: Estimating causality between smoking and abdominal obesity by Mendelian randomization. Image Credit: kong-photo / Shutterstock.com

    How does smoking affect obesity?

    Smoking leads to several chronic disorders, particularly cardiovascular and respiratory diseases. In fact, smokers often have more abdominal fat as compared to non-smokers, which further increases their risk of cardiometabolic diseases.

    It remains unclear whether the association between body fat distribution and smoking is causal. Genetic variants associated with exposure traits have been used as instrumental variables by MR studies to assess this potentially causal relationship. MR is similar to a naturally randomized controlled trial as, during conception, paternal and maternal alleles are randomly allocated.

    Previously, MR studies have explored the causal relationship between the heaviness of smoking and abdominal obesity using a single genetic variant. Two studies noted no causal relationship, whereas a third suggested a causal link between the number of cigarettes smoked each day and the waist-hip ratio (WHR), even after controlling for the body mass index (BMI). 

    About the study

    The current causal analysis using summary effect estimates (CAUSE) study involved two-sample MR analyses to quantify the effect of smoking initiation, heaviness, and life-time smoking on abdominal adiposity. To this end, genome-wide association studies (GWAS) summary statistics were obtained from the GWAS and Sequencing Consortium of Alcohol and Nicotine Use (GSCAN), United Kingdom Biobank, and Genetic Investigation of Anthropometric Traits (GIANT) Consortium.

    All study participants were of European ancestry. Exposure traits included smoking initiation, heaviness, and lifetime smoking were used, whereas outcome traits including WHR, as well as waist and hip circumferences (WC and HC) were used. The outcome traits were considered with and without adjustment for BMI.

    Study findings

    Lifetime smoking and smoking initiation causally increased abdominal adiposity, independent of socio-economic status, alcohol consumption, and other factors. Visceral fat or visceral adipose tissue (VAT) increased more than abdominal subcutaneous fat (ASAT).

    The causal relationship between abdominal fat and smoking heaviness could not be established. However, reverse causality analyses indicated that smoking heaviness could be increased causally by abdominal adiposity.

    Previous studies have used a single genetic variant in the CHRNA3/5 locus to establish causality between abdominal adiposity and smoking heaviness, both of which did not identify a causal relationship between these two factors. The Wald ratio estimates for the CHRNA3/5 locus in the current study observed causal effects; however, upon instrumenting smoking heaviness with all known genetic loci, this effect was not present. 

    Consistent with previous studies, two-sample MR analyses with 13 smoking heaviness variants showed negative causality between BMI and smoking heaviness due to the CHRNA3/5 locus. Moreover, LHC-MR and CAUSE analysis failed to establish causality between lower BMI and smoking heaviness, thus suggesting a pleiotropic effect of the CHRNA3/5 locus on BMI and smoking heaviness, rather than a causal effect.

    Smoking could lead to higher abdominal fat by increasing ASAT or visceral fat. The results for magnetic resonance imaging (MRI)-based adipose depot volumes suggested increased VAT to be primarily responsible for higher abdominal adiposity, rather than ASAT, which is consistent with the findings in existing research.

    Conclusions

    Lifetime smoking and smoking initiation may causally lead to higher abdominal and particularly visceral fat. Thus, public health efforts to reduce and prevent smoking could aid in lowering abdominal fat and the associated risk of chronic illnesses.

    The strengths of the current study include the application of different complementary MR methods and sensitivity analyses, as well as the use of large-scale GWAS summary-level data to reduce reverse causality, sample overlap, and pleiotropic effects.

    The main limitation of the present study involves the presence of residual pleiotropic effects and their influence on causal estimates. These effects could not be completely removed, despite performing multiple sensitivity analyses.

    Additionally, in the sub-sample of current smokers, the sample size for body fat distribution was small. This restricted the statistical power of the analysis of smoking heaviness. Another limitation involved the inability to evaluate the effect of smoking cessation on body fat distribution.

    Importantly, cigarettes depict unstandardized tobacco doses, which could have had a non-negligible impact on the accuracy of the estimates for smoking heaviness. Furthermore, the study population, which was restricted to individuals of European genetic ancestry, limits the generalizability of the study findings to other diverse populations.

    Journal reference:

    • Carrasquilla, G. D., Garcia-Urena, M., Romero-Lado, M. J., & Kilpelainen, T. O. (2024). Estimating causality between smoking and abdominal obesity by Mendelian randomization. Addiction. doi:10.1111/add.16454

    [ad_2]

    Source link

  • Feedback loop involving estrogen linked to women’s higher propensity to nicotine addiction

    Feedback loop involving estrogen linked to women’s higher propensity to nicotine addiction

    [ad_1]

    A newly discovered feedback loop involving estrogen may explain why women might become dependent on nicotine more quickly and with less nicotine exposure than men. The research could lead to new treatments for women who are having trouble quitting nicotine-containing products such as cigarettes.

    Sally Pauss is a doctoral student at the University of Kentucky College of Medicine in Lexington. She led the project.

    “Studies show that women have a higher propensity to develop addiction to nicotine than men and are less successful at quitting,” said Pauss, who is working under the supervision of Terry D. Hinds Jr., an associate professor. “Our work aims to understand what makes women more susceptible to nicotine use disorder to reduce the gender disparity in treating nicotine addiction.”

    The researchers found that the sex hormone estrogen induces the expression of olfactomedins, proteins that are suppressed by nicotine in key areas of the brain involved in reward and addiction. The findings suggest that estrogen–nicotine–olfactomedin interactions could be targeted with therapies to help control nicotine consumption.

    Pauss will present the research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, which will be held March 23–26 in San Antonio.

    Our research has the potential to better the lives and health of women struggling with substance use. If we can confirm that estrogen drives nicotine seeking and consumption through olfactomedins, we can design drugs that might block that effect by targeting the altered pathways. These drugs would hopefully make it easier for women to quit nicotine.”


    Sally Pauss, doctoral student, University of Kentucky College of Medicine

    For the new study, the researchers used large sequencing datasets of estrogen-induced genes to identify genes that are expressed in the brain and exhibit a hormone function. They found just one class of genes that met these criteria: those coding for olfactomedins. They then performed a series of studies with human uterine cells and rats to better understand the interactions between olfactomedins, estrogen and nicotine. The results suggested that estrogen activation of olfactomedins -; which is suppressed when nicotine is present -; might serve as a feedback loop for driving nicotine addiction processes by activating areas of the brain’s reward circuitry such as the nucleus accumbens.

    The researchers are now working to replicate their findings and definitively determine the role of estrogen. This knowledge could be useful for those taking estrogen in the form of oral contraceptives or hormone replacement therapy, which might increase the risk of developing a nicotine use disorder.

    The investigators also want to determine the exact olfactomedin-regulated signaling pathways that drive nicotine consumption and plan to conduct behavioral animal studies to find out how manipulation of the feedback loop affects nicotine consumption.

    [ad_2]

    Source link

  • A paramedic was skeptical about this Rx for stopping repeat opioid overdoses. Then he saw it help.

    A paramedic was skeptical about this Rx for stopping repeat opioid overdoses. Then he saw it help.

    [ad_1]

    Fire Capt. Jesse Blaire steered his SUV through the mobile home park until he spotted the little beige house with white trim and radioed to let dispatchers know he’d arrived.

    There, Shawnice Slaughter waited on the steps, wiping sleep from her eyes.

    “Good morning, Shawnice,” Blaire said. “How are you feeling today?”

    “I’ve been good, I’ve been good,” Slaughter said. “Much better.”

    Three days earlier, Blaire — a paramedic who leads the fire department’s emergency medical team — met Slaughter at a nearby hospital. She had overdosed on opioids. It took four vials of an overdose reversal medication and dozens of chest compressions to get her breathing again.

    At the hospital, Blaire told Slaughter about a free program that could help. It wouldn’t just connect her with a recovery center but would also get her doctors’ appointments, plus rides there. More important, she would get medicine to alleviate withdrawal symptoms so she wouldn’t search for drugs to ease the sickness. Blaire would bring that medication, daily, to her home.

    “I have a son,” Slaughter, 31, told Blaire. “I need to be alive for him.”

    Every morning since, Blaire had driven over for a check-in. He reminded Slaughter of appointments and took note of what she needed: clothes, food, help with bills.

    And at the end of each visit, from a lockbox in the back of his car, he dispensed to her a couple of tiny, lifesaving tablets.

    Those tablets — a medicine called buprenorphine — represent a tidal change in the way counties in Florida and other states are addressing the opioid crisis. The idea: Get addiction medication to people who need it by meeting them where they are. Sometimes, that’s on the street. Sometimes, it’s in the driveway of a big house with a swimming pool. Sometimes on the steps of a modest home like Slaughter’s.

    ********

    For a long time, many people who could benefit from buprenorphine, commonly known by the brand name Subutex, couldn’t get it.

    Until recently, doctors needed a federal waiver to prescribe it to treat opioid use disorder. Amid misconceptions about treating opioid use disorder with medication, only about 5% of doctors nationally underwent the training to qualify. And in 2021, only 1 in 5 people who could have benefited from opioid addiction medication were receiving buprenorphine or another drug therapy.

    But as evidence supporting the drug’s efficacy grew and the urgency mounted to curb opioid deaths, Congress axed the waiver requirement in late 2022, clearing the way for greater availability.

    And in rare cases, such as in Ocala, medics on the front lines began bringing treatment to patients’ front doors.

    In Florida, the state-run Coordinated Opioid Recovery Network, known as the CORE Network, provides guidelines on medicine distribution to areas hit hard by overdoses. Services through the network are free for patients, funded by money from the state’s opioid settlement.

    The network looks different in each of its 13 counties. Not all hand-deliver buprenorphine. But the common goal is to create a single entry point for services that have typically been siloed and difficult for patients to navigate, such as mental health care and housing support.

    In a recovery landscape rife with shoddy facilities and prohibitive price tags, simplifying the path for patients stands to make a meaningful difference.

    “We know that the more people are in contact with services, the more they’re treated with respect, the more likely they are to reduce or cease drug use,” said Susan Sherman, a public health professor at Johns Hopkins University.

    As opioid settlement dollars continue to come in, state officials have said they hope to expand to more counties.

    ********

    Becoming a firefighter and paramedic satisfied Blaire’s craving for adrenaline and his conviction, informed in part by his Christian background, that he was put on this Earth to help others.

    At 20, he imagined responding to car crashes and heart attacks, broken bones and punctured flesh. But after years on the job with Ocala Fire Rescue, the calls began to change.

    At first, Blaire felt some resentment toward the people overdosing. His team was suddenly responding to hundreds of such calls a year. He viewed drug use as a moral failure. What if a grandmother had a heart attack or a kid drowned while his team was on an overdose call?

    Unlike with other emergencies, he never really felt he was saving a life when responding to an overdose. It was more like delaying death.

    Over and over, he’d pump a patient full of naloxone, an overdose reversal medication often known by one of its brand names, Narcan, and drop them at the hospital, only to find they’d overdosed again after being discharged. One Christmas, he said, he responded to the same person overdosing five times on a single shift.

    “I didn’t understand it. I thought that they wanted to die,” said Blaire, 47. “I’m embarrassed to say that now.”

    About a decade ago, the scope of the epidemic had already come into full view to Blaire’s crew. It seemed the team was responding to overdoses at big houses in wealthy neighborhoods nearly as often as they were in the park and under the bridge.

    One week, his team went to a home on a cul-de-sac with two kids and a swing set — the kind of place families take their children trick-or-treating.

    The dad had overdosed. The next week, it was the mom.

    “Money can mask any problem, but we’ve seen it from the top to the bottom,” Blaire said.

    Over time, Blaire began to understand addiction as the disease it is: a physiological change to someone’s brain that traps them in a dangerous cycle. Maybe it started with a prescription painkiller after surgery, or an indulgence at a party, but the majority of people weren’t using drugs to get high, he realized. They were using them to avoid being sick.

    “Imagine the worst flu you’ve ever had, then make it a lot worse,” Blaire said.

    When a person dependent on opioids stops taking them, their body goes into withdrawal, often accompanied by shakes, nausea, fever, sweating, and chills. Though rare, people can die from opioid withdrawal syndrome. Still, historically, the emergency health care system has focused on reversing overdoses, rather than treating the withdrawal side effects that keep people returning to drugs.

    In the past, Blaire said, he saw patients released from the hospital with little more than a phone number for a recovery center. Getting an appointment could be challenging, not only because of wait times or insurance complications, but because the patients weren’t stable — they were in withdrawal. To make it through the day, Blaire said, they’d often use again.

    “‘Good luck, you’re on your own,’” Blaire said. “That’s how it was. And that doesn’t work for somebody who is sick.”

    Under Blaire’s leadership, Ocala Fire Rescue sought to stop the revolving door by launching its Community Paramedicine program and the Ocala Recovery Project in 2020.

    They modeled it after overdose quick-response teams around the country, which vary in makeup. These mobile teams, typically helmed by paramedics like Blaire, connect people who have overdosed with services aimed at stabilizing them long-term. On some, a registered nurse embeds with paramedics in an ambulance or SUV. Others have a therapist or peer recovery coach on board. Some are bare-bones: a single responder with a phone on 24 hours a day. Some get in touch with patients through a call or a home visit after a reported overdose.

    Others, like Blaire’s team, intercept patients at the hospital.

    Blaire likens the system to that of a trauma alert — a message sent to medical centers to ready a response to near-fatal car wrecks or shootings. When a trauma alert goes out, operating tables are cleared, CT scanners are prepped, and responders stand by for arrival.

    “We set the same system up for overdoses,” Blaire said.

    Now, when somebody in Ocala overdoses, whether it’s on opioids, alcohol, meth, or cocaine, an alert goes out, notifying Blaire and his team, a peer recovery coach, a behavioral health specialist, and a local recovery center.

    His team usually beats the ambulance to the hospital.

    The next day, team members follow up at the patient’s home.

    Then, last May, under the guidance of the EMS medical director, Blaire’s team started offering addiction medication to opioid users, too.

    Since then, Blaire said, his team has connected 149 patients with treatment. Only 28 of them have needed additional intervention, he said.

    ********

    When Blaire first heard about buprenorphine, he was skeptical.

    How could giving somebody with an addiction more narcotics help?

    That common response misunderstands the reality of addiction, said Nora Volkow, director of the National Institute on Drug Abuse.

    People perceive that one drug is being substituted for another, Volkow said. Instead, the use of medications like buprenorphine is more akin to those that treat other psychiatric conditions, like mood disorders or depression.

    Research shows that opioid addiction medication — including drugs like methadone — can greatly reduce the risk of overdose deaths, and increase a person’s retention in treatment. But a study out of the New York University Grossman School of Medicine found that nearly 87% of people with opioid use disorders don’t receive any.

    Such addiction medications work by stimulating opioid receptors in the brain.

    Opioids — like oxycodone or fentanyl — are what experts refer to as “full agonists.” Imagine an opioid receptor as a rounded bowl. A full agonist — like fentanyl — fits perfectly in that bowl and latches tightly to the receptor.

    Buprenorphine is a “partial agonist.” It fits in the bowl — and satiates a craving — but doesn’t completely bind like a full agonist. Instead, it eliminates withdrawal symptoms so people won’t get sick or crave illicit drugs, without producing a high. Second, it counteracts the effects of other drugs, so a person can’t overdose on other opioids like fentanyl or heroin while taking it.

    And for somebody who already uses opioids, overdosing from buprenorphine is nearly impossible.

    “They help a person regain control of their everyday life,” Volkow said.

    ********

    On this Monday in January, Blaire pulled into Beacon Point, a local treatment center, just past 2 p.m.

    He’d spent his morning calling on people like Slaughter, but now he was meeting paramedics from his team. After nearly three weeks of home visits, a man in the recovery network program was set to have his first appointment with a doctor.

    Blaire has found that once people are stable on buprenorphine, more often than not they want to get into a treatment program.

    While Blaire waited, a woman walking out of the center approached, smiling.

    “I just got my first clean urine analysis,” she said. “I’m doing great, I’m so excited.”

    “That’s awesome news,” Blaire said, a smile stretched across his face. He’s often stoic, straight-laced, with combed hair and aviators. But when he lights up, his all-business exterior gives way to gentleness.

    Jacqueline Luciano is sober for the first time in 30 years. She’s proud, glowing, and Blaire is proud, too.

    Luciano first came to Blaire through a referral when she was living at a women’s shelter. She said she had $20 in her pocket and wanted to get high — needed to.

    Fentanyl withdrawal had left her shaky and cold. Her stomach was seizing, her muscles spasming. To quell the agony that day in early January, she went on the hunt.

    Luciano said she had first used drugs when she was 9. Her family had been torn apart by pills and powders, she said, a sickness she’d inherited.

    But this time, a woman — “like an angel” — passed her a number for someone who she promised could guide her into a brighter future, blame-free. Luciano, 39, paused, skeptical.

    Then she gave Blaire a call.

    For about a week, Blaire delivered her a daily dose of buprenorphine using a Safe RX bottle — essentially a trackable pill bottle with a lock code to limit who can open it. He helped connect her with food and clothing donations.

    And as Luciano started to feel more like herself, absent of cravings, she began to hope.

    Blaire got her an appointment with doctors at Beacon Point, then drove her to her first screening. Now, in the parking lot, she thanked him for everything.

    “It made all the difference in the world,” Luciano told Blaire. “I really didn’t think that I could get better. I didn’t. But I am.”

    As a tear rolled down Luciano’s face, Blaire’s phone rang.

    ********

    The call came from the health department. A man in his 40s or 50s had come some 40 miles from Gainesville, Florida, for help, steered through word of mouth.

    He’d tried to get into a recovery center there but said he was turned away. Something about insurance and a criminal record had stood in the way.

    It’s a pattern that drives Blaire crazy. He’d seen it a lot before his team was formed. People would get a moment of courage or clarity, only to be told “not yet.”

    “Your first answer has to be ‘yes,’” he said. “‘Yes, I can help you.’”

    He knew about a woman who had come from 25 miles out of town, then was told to come back days later. She didn’t have a car or a home to return to.

    “They didn’t even offer her a ride,” Blaire said. “Sometimes you only have one shot.”

    Blaire has learned that building trust starts with a small offering. A car ride. A sandwich. Help getting a government ID. Anything to show that you care, that you’re useful. That you see someone trying.

    Outside the health department, a man in muddied jeans and a frayed T-shirt stood waiting on the curb. He introduced himself as Jetson and didn’t give a last name. Blaire shook his hand before they loaded into the car.

    “So what brings you this way?” Blaire asked, once both were buckled in.

    “I heard there were services here,” Jetson said, his voice gruff, quivering. “I’ve tried to stop using so many times, but I keep messing it up.”

    Jetson shook his head.

    “Well, I’m glad you found us,” Blaire said. He asked the man if he wanted to go to the recovery center for a screening. He did.

    Over the 10-minute drive to Beacon Point, Blaire and Jetson talked, not about drugs or meds, but life. Baseball. Cabbage (good when fried).

    When they pulled up, Blaire handed Jetson a card.

    “Please call me,” Blaire said. “If you need anything. We can get you help.”

    For a moment, the men sat there. Jetson pulling at his fingers. Taking deep breaths.

    Then, he got out of the car — Blaire’s card in hand — and walked through the glass door.

    This article was produced in partnership with the Tampa Bay Times.




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link